News
PHGUF
1.180
NaN%
--
Pharming: Faltering Rare-Disease Franchise With Two Potentially Transformative Late-Stage Assets
Seeking Alpha · 16h ago
Pharming Group Steps Up Investor Outreach With September Conference Lineup
TipRanks · 17h ago
Pharming launches Joenja in Japan, first market to treat APDS children from age four
TipRanks · 08/13 05:45
Pharming Group Earnings Call: Growth Story Amid Pressure
TipRanks · 07/31 00:20
Pharming cuts FY26 revenue view to $375M-$395M from $405M-$425M
TipRanks · 07/30 10:00
Pharming reports Q2 EPS 2c, consensus 6c
TipRanks · 07/30 09:55
Pharming trims 2026 revenue outlook as Joenja growth offsets RUCONEST pressure
TipRanks · 07/30 05:44
Buy Rating Reaffirmed on Joenja’s European Expansion and Pediatric FDA Catalyst; $37 Price Target Maintained
TipRanks · 07/06 10:35
Pharming: Profitable Core, Advancing Pipeline Underpin Buy Rating and Maintained $37 Price Target
TipRanks · 06/23 11:55
Pantginis Reiterates Buy on Pharming as Joenja’s Global Expansion Advances; $37 Price Target Maintained
TipRanks · 05/26 10:26
Pharming’s Joenja granted marketing authorization by European Commission
TipRanks · 05/22 19:36
Pharming Group Balances Near-Term Strain With Joenja Growth
TipRanks · 05/20 05:13
Pharming Group (PHAR) Gets a Buy from Canaccord Genuity
TipRanks · 05/08 16:59
Pharming price target lowered to $40 from $41 at Oppenheimer
TipRanks · 05/08 15:56
Pharming Group Balances Short-Term Strain With Pipeline Gains
TipRanks · 05/08 01:23
Pharming reports Q1 EPS 1c, consensus 0c
TipRanks · 05/07 11:39
Pharming sees FY26 revenue $405M-$425M, consensus $411.9M
TipRanks · 05/07 11:39
Pharming initiated with a Buy at Canaccord on growth potential
TipRanks · 04/10 11:00
Pharming initiated with a Buy at Canaccord
TipRanks · 04/10 09:30
Pharming announces approval of Joenja in Japan for patients aged 4 years and old
TipRanks · 03/24 15:06
More
Webull provides a variety of real-time PHGUF stock news. You can receive the latest news about Pharming Group through multiple platforms. This information may help you make smarter investment decisions.
About PHGUF
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.